Early Access in Oncology: Why Is It Needed?

  • Giovanni Apolone Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italia
  • Andrea Ardizzoni Policlinico Sant’Orsola-Malpighi, Bologna, Italia
  • Giuliano Buzzetti Consulta Prevenzione Rischio Cardiovascolare, Dephaforum S.r.l., Milano, Italia
  • Mario Alberto Clerico Presidente CIPOMO
  • Pierfranco Conte Rete Oncologica Veneta, Padova, Italia
  • Filippo de Braud Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italia
  • Francesco De Lorenzo European Cancer Patient Coalition, Bruxelles, Belgio
  • Maria Gabriella Ferrandina Fondazione Policlinico Universitario A. Gemelli, Roma, Italia
  • Armando Genazzani Università degli Studi del Piemonte Orientale, Novara, Italia
  • Stefania Gori Presidente AIOM, Ospedale Sacro Cuore Don Calabria, Negrar (Verona), Italia
  • Michele Maio Azienda Ospedaliera Universitaria Senese, Siena, Italia
  • Mauro Patroncini Dephaforum S.r.l., Milano, Italia
  • Francesco Perrone Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Napoli, Italia
  • Giovanni Scambia Fondazione Policlinico Universitario A. Gemelli, Roma, Italia
  • Giovanna Scroccaro Direzione Farmaci, Dispositivi medici e Protesica, Area Sanità e Sociale, Regione Veneto, Venezia, Italia
Keywords: Cancer drugs, early access, price and reimbursement, clinical value


Timely access to cancer therapies with significant added value is an important expectation for patients and a primary responsibility for every public health service. Over time, collaboration between the pharmaceutical industry and regulatory agencies has made it possible to agree to implement tools in order to accelerate the development and approval of potentially innovative drugs. In Italy, too, several early access tools have been introduced. In June 2018 a panel of experts agreed on the need to simplify and streamline early access assessment criteria and processes. The panel developed a proposal to categorize cancer drugs eligible for early access. In the curative setting, the evaluation of the medical need should take into account both the relapse rate, attributed on the basis of the disease free survival (DFS), and the strength of the recommendations of the Italian Association of Medical Oncology (AIOM) for any therapeutic alternatives already available. The panel then found it appropriate to use the European Society for Medical Oncology (ESMO) criteria for the evaluation of the clinical benefit. The sum of the scores assigned to the three parameters should allow the clinical value of the drug to be defined and, consequently, the priorities for early access to be established. This multiparameter approach can also be adapted to the non-curative setting. The early access process should be reserved for first-in-class drugs and should provide for the recognition of a conditional reimbursement within 60 days, financed by a special fund. The proposal developed by the panel has the objective of starting a proactive discussion with the Italian health authority.
How to Cite
Apolone G, Ardizzoni A, Buzzetti G, Clerico MA, Conte P, de Braud F, De Lorenzo F, Ferrandina MG, Genazzani A, Gori S, Maio M, Patroncini M, Perrone F, Scambia G, Scroccaro G. Early Access in Oncology: Why Is It Needed?. GRHTA [Internet]. 20Jun.2019 [cited 23Jan.2021];6(1). Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/461
Point of View